--- title: "Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/286408551.md" description: "Halozyme Therapeutics CEO Helen Torley sold 20,000 shares at $71.75 each, totaling $1.435 million, reducing her ownership by 2.54%. Post-transaction, she holds 767,780 shares valued at approximately $55.1 million. This sale was part of a pre-arranged trading plan. Torley has made several other sales recently, with the stock's performance showing a 52-week range of $47.50 to $82.22. The company reported strong quarterly earnings, exceeding estimates, and has set FY 2026 EPS guidance between 7.750-8.250." datetime: "2026-05-14T11:30:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286408551.md) - [en](https://longbridge.com/en/news/286408551.md) - [zh-HK](https://longbridge.com/zh-HK/news/286408551.md) --- # Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $55,088,215. This represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Helen Torley also recently made the following trade(s): - On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. - On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total transaction of $635,000.00. - On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. - On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00. - On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $1,393,800.00. ## Halozyme Therapeutics Price Performance * * * * * * Halozyme Therapeutics stock opened at $70.03 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company's 50 day moving average price is $65.71 and its two-hundred day moving average price is $68.63. The company has a quick ratio of 3.66, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock has a market cap of $8.30 billion, a P/E ratio of 25.19, a P/E/G ratio of 0.29 and a beta of 0.89. Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the business posted $1.11 EPS. Halozyme Therapeutics's quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current year. ## Institutional Inflows and Outflows Hedge funds have recently bought and sold shares of the business. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC grew its stake in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC grew its stake in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 343 shares in the last quarter. Richardson Financial Services Inc. grew its stake in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 198 shares in the last quarter. Finally, Clearstead Advisors LLC grew its stake in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 265 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors. ## Analyst Upgrades and Downgrades Several equities research analysts have recently issued reports on HALO shares. TD Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, April 29th. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 19th. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday. Finally, Wall Street Zen lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Saturday, February 21st. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $80.67. **Get Our Latest Stock Analysis on Halozyme Therapeutics** ## More Halozyme Therapeutics News Here are the key news stories impacting Halozyme Therapeutics this week: - Positive Sentiment: Halozyme beat Q1 estimates, with revenue rising about 42% year over year to $376.7 million and EPS coming in above expectations, helping support investor confidence in the company’s growth outlook. Article Title - Positive Sentiment: The company also highlighted a new $1 billion share repurchase authorization and reiterated full-year guidance, which can be viewed as a signal of management confidence and a potential support for the share price. Article Title - Positive Sentiment: Halozyme announced a global collaboration and license agreement with GSK for its ENHANZE drug-delivery technology, potentially expanding its long-term royalty stream if partnered programs progress. Article Title - Neutral Sentiment: Morgan Stanley trimmed its price target on Halozyme to $93 from $96, but kept an overweight rating, so the note was not a major negative for the stock. Article Title - Negative Sentiment: CEO Helen Torley disclosed two recent stock sales totaling 30,000 shares under a pre-arranged 10b5-1 plan, which may weigh on sentiment even though the trades were planned in advance. Article Title ## Halozyme Therapeutics Company Profile (Get Free Report) Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration. The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix. ## Featured Articles - Five stocks we like better than Halozyme Therapeutics - Oklo Stock Could Be Ready for Another Massive Run - D-Wave Earnings Looked Weak, But Investors May Be Missing This - Nebius Upside Expands as AI Feedback Loop Intensifies - Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell _This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\]._ Insider Buying or Selling at Halozyme Therapeutics? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Halozyme Therapeutics and related companies. From Our Partners Is this AI lab Elon’s SpaceX lifeline? Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ... Chaikin Analytics Read this or regret it forever Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P... Porter & Company Collect $1,170 a month from silver I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens... Investors Alley Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer... InvestorPlace SpaceX IPO Warning: Before you buy any SpaceX shares, read this. The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl... Weiss Ratings SpaceX just filed. The clock is ticking. Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re... The Oxford Club Millionaire trader: “Buy this before May 15.” Hedge fund legend Larry Benedict - who beat the S&P 500 by 18 times in 2025 and generated $95 million for clie... Brownstone Research The system holding the dollar together is gone… Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every... Golden Portfolio ### Related Stocks - [HALO.US](https://longbridge.com/en/quote/HALO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [WFC.US](https://longbridge.com/en/quote/WFC.US.md) - [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md) - [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md) - [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md) - [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md) - [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md) - [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md) ## Related News & Research - [Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/286000530.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)